You are here
A Bargain at $850,000? Luxturna Costs Less Than Predicted
Spark Therapeutics Inc. has priced its new gene therapy for a rare form of blindness at $850,000. That may not seem like much of a bargain, but it starts to sound better when you consider that the industry expected a cost of $1 million.
The company said the price tag for voretigene neparvovec-rzyl (Luxturna) reflects patient and insurer concerns about access and cost, according to Reuters. Luxturna, approved in December by the FDA, is designed to be given just once.
Spark said it has created a number of payment models to help reduce costs for insurers by allowing installment payments over a number of years and to ensure financial concerns do not hinder access for patients. For instance, the company said, it has reached agreement in principle with Harvard Pilgrim make Luxturna available under an outcomes-based rebate arrangement, and it is negotiating with other insurers. Such arrangements could include Spark paying rebates if patient outcomes fail to meet specified thresholds for efficacy in both the short term (30–90 days) and long term (30 months).
“The price reflects the stakeholder considerations we have learned about these past months,” the company said in a statement, “and our need to build a sustainable company that addresses the unmet needs of patients with genetic diseases.”
Luxturna has the highest list price of any drug, although the ultimate cost for patients and insurers may be less than for other expensive drugs that must be given every year for life.
“We believe these pricing initiatives for a one-time treatment may widen the availability of the drug for patients,” Justin Kim, an analyst at Cantor Fitzgerald, said in a research note.
Luxturna treats inherited retinal disease caused by defects in a gene known as RPE65, which tells cells to produce an enzyme critical for normal vision. The condition affects between 1,000 and 2,000 people in the United States. The product works by delivering, via an eye injection, some 150 billion viral vector particles containing a correct copy of the RPE65 gene to retinal cells, restoring their ability to make the needed enzyme.
Clinical trials of Luxturna showed that 93% of participants experienced some improvement in their functional vision as measured by their ability to navigate obstacles in poor light after one year. It is unclear how long the benefit of the treatment will ultimately last.